US Patent
US9604018 — Aerosol therapy device
Formulation · Assigned to PARI Pharma GmbH · Expires 2033-05-16 · 7y remaining
Vulnerability score
42/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects an aerosol therapy device with a specific design for generating and administering aerosol.
USPTO Abstract
The disclosure relates to an aerosol therapy device including: a housing; an aerosol generator, which is arranged in the housing; an air inlet, which is formed in the housing upstream of the aerosol generator; and an air outlet, which is formed in the housing downstream of the aerosol generator to administer the aerosol produced, wherein an air flow from the air inlet to the air outlet can be generated by a negative pressure at the air outlet, wherein the air flow flows around the aerosol generator, wherein a truncated-cone-shaped flow channel, the central axis of which extends in a curved manner, is arranged between the aerosol generator and the air outlet.
Drugs covered by this patent
- glycopyrrolate (Glycopyrrolate) · Yonsei University
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.